TPD52: A Novel Vaccine Target for Prostate Cancer
Annual rept. 1 Sep 2008-31 Aug 2009
TEXAS TECH UNIV HEALTH SCIENCES CENTER LUBBOCK
Pagination or Media Count:
As outlined in our approved statement of work, the goals of this Award are to test the efficacy of TPD52-based vaccines in the TRAMP murine model of prostate cancer, and to characterize vaccine induced mechanisms of tumor immunity. Specifically, we have begun to evaluate the ability of TPD52-DNA-based vaccines given intramuscularly to induce immune responses capable of rejecting the formation of subcutaneous tumors following challenge with TRAMP-C1 or TRAMP-C2 tumor cells. Over the past 12-18 months we have made the following significant findings or accomplishments First, DNA vaccines encoding the human orthologue of TPD25 hD52 induced increased protection from tumor challenge compared to murine TPD52 mD52 DNA vaccines suggesting the xenogeneic antigen may be more immunopotent. Second, TPD52-DNA vaccines administered intramuscularly appear to be less effective than TPD52- DNA vaccines admixed with soluble GMSCF protein administered subcutaneously. Our recent work in other murine tumor models suggests that protein-based TPD52 vaccines may be more effective than DNA-based TPD52 vaccines. To prepare to address this in the TRAMP prostate tumor model we established efficient, reliable methods for generating and purifying both murine and human TPD52 recombinant protein for future xenogeneic, prime-boost vaccine studies.
- Medicine and Medical Research